StockData

iRhythm vs Tandem Diabetes Care

IRTC and TNDM side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IRTC and TNDM compare

iRhythm is the larger company, worth 2.5 times as much as Tandem Diabetes Care ($3.0B against $1.2B).

iRhythm grew revenue faster over the last twelve months (25.6% versus 4.0% for Tandem Diabetes Care).

iRhythm keeps more of each dollar of sales as profit, with a net margin of −1.7% compared with −6.1% at Tandem Diabetes Care.

iRhythm scores higher on the StockData Score (9 against 6 for Tandem Diabetes Care), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIRTCTNDM
Size and price
Market cap$3.0B$1.2B
Share price$89.67$17.06
Change, 1 year−47.5%−8.3%
Change, 5 years−8.5%−86.8%
Beta (5Y)1.390.89
Employees2,400500K
StockData Score
Total score9 (better)6
Valuation score12 (better)
Growth score4 (better)1
Performance score3 (better)2
Health score11
Dividend score00
Valuation
P/S3.6×1.1× (better)
P/B15.9×9.1× (better)
P/FCF75.8×–
FCF yield1.3% (better)−2.2%
Fair value$92.19$24.24
Margin of safety2.7%29.6% (better)
Growth
Revenue growth (TTM)25.6% (better)4.0%
Revenue growth, 5Y average23.0% (better)15.3%
Profitability
Gross margin71.5% (better)56.0%
Operating margin−3.0% (better)−4.4%
Net margin−1.7% (better)−6.1%
FCF margin4.7% (better)−2.6%
Return on equity−9.6% (better)−48.0%
Return on invested capital–−17.9%
Financial health
Debt / equity–4.62
Interest coverage−1.9× (better)−5.2×
Current ratio3.85 (better)3.18
Altman Z-score2.20 (better)0.47
Piotroski F-score5 (better)3
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions108%113%
Held by insiders2.1%1.2%
Insider net buying, 12 months−$24.4M−$36.9K (better)
Short interest, % of float10.1%23.5%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.